Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
TREACE MEDICAL CONCEPTS, INC.
Report date June 02, 2023 · Filed June 08, 2023
Section 16 reporting ended · disclosed 2023-06-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-06-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-06-02 · Sale · Disposed 48,503 · Balance 1,042,318 Row 2 · 2023-06-05 · Sale · Disposed 1,042,318 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2023 Filed Jun 8, 2023 16:28 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 1,042,318 | $26.51 | $27,631,850.18 |
DisclosureSEC source: 0001209191-23-035400 · doc4.xml · nonDerivative · entry 2 BAYS F BARRY · CIK 0001183554 · Former Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| June 02, 2023 Filed Jun 8, 2023 16:28 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 48,503 | $26.51 | $1,285,814.53 |
DisclosureSEC source: 0001209191-23-035400 · doc4.xml · nonDerivative · entry 1 BAYS F BARRY · CIK 0001183554 · Former Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,042,318 Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 11,600 | $25.35 | $294,031.00 |
DisclosureSEC source: 0001209191-23-026167 · doc4.xml · nonDerivative · entry 2 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,090,821 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.1500 to $25.6950 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 16,204 | $25.55 | $414,012.20 |
DisclosureSEC source: 0001209191-23-026167 · doc4.xml · nonDerivative · entry 1 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,102,421 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.4400 to $25.7850 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 12, 2023 Filed Apr 13, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 36,370 | $26.12 | $950,104.42 |
DisclosureSEC source: 0001209191-23-024260 · doc4.xml · nonDerivative · entry 3 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,118,625 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.8400 to $26.5050 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 5,026 | $27.28 | $137,108.27 |
DisclosureSEC source: 0001209191-23-024260 · doc4.xml · nonDerivative · entry 2 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,154,995 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $27.1500 to $27.5700 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 44,764 | $26.28 | $1,176,286.01 |
DisclosureSEC source: 0001209191-23-024260 · doc4.xml · nonDerivative · entry 1 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,160,021 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $26.0100 to $26.9700 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 29, 2023 Filed Mar 30, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 32,457 | $25.28 | $820,425.33 |
DisclosureSEC source: 0001209191-23-021741 · doc4.xml · nonDerivative · entry 2 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,204,785 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.0900 to $25.5600 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 26,241 | $25.02 | $656,649.54 |
DisclosureSEC source: 0001209191-23-021741 · doc4.xml · nonDerivative · entry 1 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,237,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.8800 to $25.1600 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 9,400 | $23.25 | $218,533.08 |
DisclosureSEC source: 0001209191-23-019078 · doc4.xml · nonDerivative · entry 3 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,263,483 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.0400 to $23.6250 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 1,080 | $24.73 | $26,708.94 |
DisclosureSEC source: 0001209191-23-019078 · doc4.xml · nonDerivative · entry 2 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,272,883 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.6300 to $24.9000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 8,320 | $24.07 | $200,288.19 |
DisclosureSEC source: 0001209191-23-019078 · doc4.xml · nonDerivative · entry 1 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,273,963 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.6300 to $24.5200 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 22, 2023 Filed Feb 23, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 9,400 | $21.97 | $206,534.92 |
DisclosureSEC source: 0001209191-23-012441 · doc4.xml · nonDerivative · entry 2 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,282,283 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.7150 to $22.1800 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 9,400 | $21.74 | $204,352.24 |
DisclosureSEC source: 0001209191-23-012441 · doc4.xml · nonDerivative · entry 1 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,291,683 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.4200 to $22.0400 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 08, 2023 Filed Feb 9, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 27,731 | $21.71 | $601,901.36 |
DisclosureSEC source: 0001209191-23-008200 · doc4.xml · nonDerivative · entry 2 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,301,083 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.4000 to $22.0100 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 8,800 | $23.00 | $202,366.56 |
DisclosureSEC source: 0001209191-23-008200 · doc4.xml · nonDerivative · entry 1 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,328,814 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.8700 to $23.3100 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 25, 2023 Filed Jan 26, 2023 21:13 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 7,255 | $25.73 | $186,658.82 |
DisclosureSEC source: 0001209191-23-005131 · doc4.xml · nonDerivative · entry 3 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,337,614 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.6600 to $25.8100 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 25, 2023 Filed Jan 26, 2023 21:13 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 20,467 | $25.28 | $517,440.55 |
DisclosureSEC source: 0001209191-23-005131 · doc4.xml · nonDerivative · entry 2 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,344,869 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.6600 to $25.6500 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 21:13 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 25,921 | $26.03 | $674,744.37 |
DisclosureSEC source: 0001209191-23-005131 · doc4.xml · nonDerivative · entry 1 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,365,336 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.7700 to $26.3700 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 21,841 | $25.94 | $566,638.54 |
DisclosureSEC source: 0001209191-23-003383 · doc4.xml · nonDerivative · entry 3 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,391,257 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.5500 to $25.9900 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Due to an inadvertent error, the value in Table 1, Box 5 of the Form 4 filed on September 29, 2022 was incorrectly reported. This value corrects the aforementioned error. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 23,695 | $25.13 | $595,500.37 |
DisclosureSEC source: 0001209191-23-003383 · doc4.xml · nonDerivative · entry 2 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,413,098 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.5500 to $25.5400 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Due to an inadvertent error, the value in Table 1, Box 5 of the Form 4 filed on September 29, 2022 was incorrectly reported. This value corrects the aforementioned error. Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 9,719 | $24.32 | $236,366.08 |
DisclosureSEC source: 0001209191-23-003383 · doc4.xml · nonDerivative · entry 1 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,436,793 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.0500 to $24.755 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Due to an inadvertent error, the value in Table 1, Box 5 of the Form 4 filed on September 29, 2022 was incorrectly reported. This value corrects the aforementioned error. Read SEC document |
| December 20, 2022 Filed Dec 21, 2022 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 9,414 | $23.24 | $218,776.65 |
DisclosureSEC source: 0001209191-22-062379 · doc4.xml · nonDerivative · entry 2 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,481,333 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.8400 to $23.6500 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 9,067 | $22.86 | $207,264.37 |
DisclosureSEC source: 0001209191-22-062379 · doc4.xml · nonDerivative · entry 1 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,490,747 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.4700 to $23.0700 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 9,739 | $23.99 | $233,638.61 |
DisclosureSEC source: 0001209191-22-060617 · doc4.xml · nonDerivative · entry 2 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,499,814 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.900 to $24.170 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 9,061 | $23.97 | $217,192.17 |
DisclosureSEC source: 0001209191-22-060617 · doc4.xml · nonDerivative · entry 1 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,509,553 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.650 to $24.265 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 29, 2022 Filed Nov 30, 2022 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 9,400 | $22.18 | $208,463.80 |
DisclosureSEC source: 0001209191-22-059128 · doc4.xml · nonDerivative · entry 2 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,518,614 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.010 to $22.480 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 28, 2022 Filed Nov 30, 2022 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 9,400 | $22.09 | $207,664.80 |
DisclosureSEC source: 0001209191-22-059128 · doc4.xml · nonDerivative · entry 1 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,528,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.700 to $22.305 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 06:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 7,900 | $23.62 | $186,598.00 |
DisclosureSEC source: 0001209191-22-056467 · doc4.xml · nonDerivative · entry 4 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,537,414 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.1000 to $23.8950 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 06:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 1,500 | $22.48 | $33,720.00 |
DisclosureSEC source: 0001209191-22-056467 · doc4.xml · nonDerivative · entry 3 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,545,314 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.1050 to $23.0100 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 06:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 13,023 | $21.19 | $275,957.37 |
DisclosureSEC source: 0001209191-22-056467 · doc4.xml · nonDerivative · entry 2 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,546,814 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.0200 to $21.6000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 06:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 4,100 | $20.77 | $85,157.00 |
DisclosureSEC source: 0001209191-22-056467 · doc4.xml · nonDerivative · entry 1 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,559,837 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.0200 to $21.0150 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 19, 2022 Filed Oct 20, 2022 18:39 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 615 | $23.50 | $14,452.50 |
DisclosureSEC source: 0001209191-22-054211 · doc4.xml · nonDerivative · entry 3 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,563,937 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.39 to $23.72 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 19, 2022 Filed Oct 20, 2022 18:39 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 25,647 | $22.73 | $582,956.31 |
DisclosureSEC source: 0001209191-22-054211 · doc4.xml · nonDerivative · entry 2 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,564,552 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.39 to $23.38 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 18:39 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 25,428 | $24.02 | $610,780.56 |
DisclosureSEC source: 0001209191-22-054211 · doc4.xml · nonDerivative · entry 1 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,590,199 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.5500 to $24.3000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 18:01 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 13,500 | $23.19 | $313,051.50 |
DisclosureSEC source: 0001209191-22-053169 · doc4.xml · nonDerivative · entry 2 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,615,627 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.57 to $23.48 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 05, 2022 Filed Oct 7, 2022 18:01 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 16,274 | $22.57 | $367,271.63 |
DisclosureSEC source: 0001209191-22-053169 · doc4.xml · nonDerivative · entry 1 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,629,127 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.23 to $23.16 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 28, 2022 Filed Sep 29, 2022 18:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 23,068 | $23.03 | $531,209.90 |
DisclosureSEC source: 0001209191-22-051555 · doc4.xml · nonDerivative · entry 2 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,645,401 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.61 to $23.25 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 27, 2022 Filed Sep 29, 2022 18:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 14,424 | $22.36 | $322,491.79 |
DisclosureSEC source: 0001209191-22-051555 · doc4.xml · nonDerivative · entry 1 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,668,469 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.24 to $22.83 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 14, 2022 Filed Sep 15, 2022 18:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 9,746 | $24.15 | $235,341.54 |
DisclosureSEC source: 0001209191-22-050143 · doc4.xml · nonDerivative · entry 4 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,648,072 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.10 to $24.21 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 14, 2022 Filed Sep 15, 2022 18:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 25,075 | $23.63 | $592,472.10 |
DisclosureSEC source: 0001209191-22-050143 · doc4.xml · nonDerivative · entry 3 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,657,818 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.10 to $24.09 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 14, 2022 Filed Sep 15, 2022 18:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 13,836 | $22.90 | $316,905.28 |
DisclosureSEC source: 0001209191-22-050143 · doc4.xml · nonDerivative · entry 2 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,682,893 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.10 to $23.09 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 13, 2022 Filed Sep 15, 2022 18:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 19,700 | $22.46 | $442,391.08 |
DisclosureSEC source: 0001209191-22-050143 · doc4.xml · nonDerivative · entry 1 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,696,729 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.25 to $23.24 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 30, 2022 Filed Aug 31, 2022 17:52 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 3,800 | $20.15 | $76,570.00 |
DisclosureSEC source: 0001209191-22-048172 · doc4.xml · nonDerivative · entry 2 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,716,429 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.0600 to $20.2800 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 29, 2022 Filed Aug 31, 2022 17:52 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 8,064 | $20.10 | $162,066.24 |
DisclosureSEC source: 0001209191-22-048172 · doc4.xml · nonDerivative · entry 1 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,720,229 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.0000 to $20.6400 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:05 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | ConversionSeries A Preferred Stock · Derivative | 413,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-017458 · doc4.xml · derivative · entry 3 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 413,326 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:05 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | OtherSeries A Preferred Stock · Derivative | 9,569 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-017458 · doc4.xml · derivative · entry 2 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,326 Underlying: Common Stock · 9,569 shares Expires not disclosed F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · derivative.exercise_price: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend . F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · derivative.exercise_date: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend . F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · derivative.expiration_date: The Reporting Person received Series A Preferred Stock as a payment-in-kind dividend . Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:05 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | ConversionCommon Stock | 413,326 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-017458 · doc4.xml · nonDerivative · entry 1 BAYS F BARRY · CIK 0001183554 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,728,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.